Brought to you by 
Sutro, Pfizer sign multi-year protein drug deal
23 Feb 2023
Executive Summary
In its first licensing agreement, protein drug developer Sutro Biopharma Inc. has teamed up with Pfizer Inc. in the research, development and commercialization of peptide therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sutro, Pfizer sign multi-year protein drug deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice